Education
About Us
Working with TipRanks
Follow Us
Vivoryon Therapeutics AG (DE:05Y)
FRANKFURT:05Y
Total Valuation
Vivoryon Therapeutics AG has a market cap or net worth of €45.67M. The enterprise value is ―.
Market Cap€45.67M
Enterprise Value―
Share Statistics
Vivoryon Therapeutics AG has 26,066,809 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,066,809
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Vivoryon Therapeutics AG’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee-241.33K
Profits Per Employee-1.89M
Employee Count15
Asset Turnover-0.12
Inventory Turnover30.88
Valuation Ratios
The current PE Ratio of Vivoryon Therapeutics AG is -7.24. Vivoryon Therapeutics AG’s PEG ratio is 0.58.
PE Ratio-7.24
PS Ratio25.53
PB Ratio7.81
Price to Fair Value7.81
Price to FCF-9.30
Price to Operating Cash Flow-9.53
PEG Ratio0.58
Income Statement
In the last 12 months, Vivoryon Therapeutics AG had revenue of -3.62M and earned -28.34M in profits. Earnings per share was -1.12.
Revenue-3.62M
Gross Profit-3.10M
Operating Income-28.84M
Pretax Income-28.58M
Net Income-28.34M
EBITDA-28.35M
Earnings Per Share (EPS)-1.12
Cash Flow
In the last 12 months, operating cash flow was -14.56M and capital expenditures -5.00K, giving a free cash flow of -14.56M billion.
Operating Cash Flow-14.56M
Free Cash Flow-14.56M
Free Cash Flow per Share-0.56
Dividends & Yields
Vivoryon Therapeutics AG pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change130.34%
50-Day Moving Average1.89
200-Day Moving Average2.08
Relative Strength Index (RSI)39.61
Average Volume (3m)1.35K
Important Dates
Vivoryon Therapeutics AG upcoming earnings date is Apr 29, 2025, TBA Not Confirmed.
Last Earnings DateDec 10, 2024
Next Earnings DateApr 29, 2025
Ex-Dividend Date―
Financial Position
Vivoryon Therapeutics AG as a current ratio of 9.37, with Debt / Equity ratio of 0.07%
Current Ratio9.37
Quick Ratio9.37
Debt to Market Cap0.00
Net Debt to EBITDA―
Interest Coverage Ratio-514.95
Taxes
In the past 12 months, Vivoryon Therapeutics AG has paid -234.00K in taxes.
Income Tax-234.00K
Effective Tax Rate<0.01
Enterprise Valuation
Vivoryon Therapeutics AG EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Vivoryon Therapeutics AG has €15.27M in cash and marketable securities with €406.00K in debt, giving a net cash position of -€15.26M billion.
Cash & Marketable Securities€15.27M
Total Debt€406.00K
Net Cash-€15.26M
Net Cash Per Share-€0.59
Tangible Book Value Per Share€1.00
Margins
Gross margin is 116.52%, with operating margin of 796.60%, and net profit margin of 782.93%.
Gross Margin116.52%
Operating Margin796.60%
Pretax Margin789.39%
Net Profit Margin782.93%
EBITDA Margin783.23%
EBIT Margin787.85%
Analyst Forecast
The average price target for Vivoryon Therapeutics AG is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―